A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Clinical trial NCT06695845 · RECRUITING

Trial details

NCT number: NCT06695845
Sponsor: Jazz Pharmaceuticals
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Gastric Cancer Esophageal Cancer Gastroesophageal Cancer Colorectal Cancer Endometrial Cancer Non-small Cell Lung Cancer Ovarian Cancer Urothelial Carcinoma Salivary Gland Cancer Pancreatic Cancer HER-2 Protein Overexpression

Start date: 2025-01-14
Primary completion: 2026-12-31
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.